Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway
- Author:
- No author available
- Journal Title:
- Neural Regeneration Research
- Issue:
- 35
- DOI:
- 10.3969/j.issn.1673-5374.2013.35.001
- Key Word:
- neural regeneration;alpha-synuclein;neuronal survival;nanomolar;extracellular;phosphorylated Akt;SH-SY5Y cel;neuronal differentiation;proliferation;dopaminergic;5-bromo-2'-deoxyuridine;grants-supported paper;neuroregeneration
Abstract： Although alpha-synuclein is general y thought to have a pathological role in Parkinson’s disease, accumulative evidence exists that alpha-synuclein has a neuroprotective effect. The aim of this study was to evaluate the effect of extracellular alpha-synuclein on dopaminergic cellsurvival. We assessed cellviability using the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltertazolium bromide (MTT) assay both in undifferentiated SH-SY5Y (SHSY) cells and neuronal y-differentiated SH-SY5Y (ndSHSY) cells after 24 hour treatment with monomeric alpha-synuclein at various concentrations (0 [control], 50, 100 nmol/L, 1μmol/L). To determine whether cellviability assessed by MTT assay was affected by cellproliferation, 5-bromo-2'-deoxyuridine (BrdU) incorporation assay was per-formed. Level of both Akt and phosphorylated Akt was measured using western blot method in ndSHSY cells with or without 24 hour alpha-synuclein treatment. cellviability was increased in ndSHSY cells at the nanomolar concentration of alpha-synuclein, but not in SHSY cells. Proportion of BrdU-positive ndSHSY cells was decreased in alpha-synuclein-treated group compared with control group. Level of phosphorylated Akt in alpha-synuclein-treated group was higher compared with the control group. Our study shows that extracellular alpha-synuclein at nanomolar concentra-tion benefits dopaminergic cellsurvival via Akt pathway.
- [1]Jacqueline, Burré,Manu, Sharma,Theodoros, Tsetsenis,etc.Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.[J].2010,329(5999).
- [2]Hu J,Li HT,Du HN,etc.A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.[J].2003,42(29).
- [3]Ito S,Nakaso K,Nakashima K.Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.[J].2008,432(2).
- [4]Lee SJ.Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.[J].2008,34(1).
- [5]Thomas, Bobby,Mandir, Allen S.,West, Neva,etc.Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation.[J].2011,6(1).
- [6]Desplats,P.,Bae,E.-J.,Ho,D.-H.,etc.Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission[J].2012,32(39).
- [7]Lee, VMY,Branch, JR,Luk, KC,etc.Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells[J].2009,106(47).
- [8]Lincoln S,Kachergus J,Larvor L,etc.Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.[J].2004,364(9440).
- [9]Masliah, Eliezer,Rockenstein, Edward,Mante, Michael,etc.Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease.[J].2011,6(4).
- [10]Borghi R,Abbruzzese G,Negro A,etc.Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects.[J].2000,287(1).
- [11]Sang Myun, Park,Kwang Soo, Kim.Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.[J].1900,7.
- [12]L S, Forno.Neuropathology of Parkinson's disease.[J].1996,55.
- [13]R. Anthony Crowther,Ross Jakes,Maria Grazia Spillantini.α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies[J].1998,95(11).
- [14]Leng Y,Chuang DM.Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.[J].2006,26(28).
- [15]Di-Monte DA,Manning-Bog AB,McCormack AL,etc.Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.[J].2003,23(8).
- [16]Kruger R.,Muller T.,Woitalla D.,etc.Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease[J].1998,18(2).
- [17]Choong CJ,Say YH.Neuroprotection of alpha-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.[J].2011,32(6).
- [18]Li Y,Li G,Tao L,etc.Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP+: the involvement of PI3K/Akt pathway activation.[J].2011,202(1).
- [19]M H, Polymeropoulos,C, Lavedan,E, Leroy,etc.Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.[J].1997,276.